{"id":49094,"date":"2025-11-27T15:41:18","date_gmt":"2025-11-27T07:41:18","guid":{"rendered":"https:\/\/flcube.com\/?p=49094"},"modified":"2025-11-27T15:41:19","modified_gmt":"2025-11-27T07:41:19","slug":"sciclones-meropenem-vaborbactam-wins-gba-approval-as-first-antibiotic-under-medical-connect","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49094","title":{"rendered":"SciClone&#8217;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect"},"content":{"rendered":"\n<p><strong>SciClone Pharmaceuticals Inc.<\/strong> announced that <strong>Meropenem\/Vaborbactam for Injection<\/strong> has been approved under the <strong>\u201cHong Kong-Macau Drug and Device Access\u201d<\/strong> policy for use in designated medical institutions across the <strong>Greater Bay Area (GBA) mainland cities<\/strong>, marking the <strong>first antibiotic<\/strong> introduced through the <strong>GBA Medical Connect<\/strong> scheme and offering a breakthrough treatment for <strong>Carbapenem-resistant Enterobacterales (CRE)<\/strong> infections.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Meropenem\/Vaborbactam for Injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>SciClone Pharmaceuticals Inc.<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (via GBA Medical Connect policy)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Access approval for designated GBA medical institutions<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Serious infections caused by CRE and other resistant bacteria<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First antibiotic<\/strong> approved under GBA Medical Connect<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>Approved in EU (cUTI, cIAI, HAP\/VAP, bacteremia) and US (cUTI); HK\/Macau approved Apr\u202f2024<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Novel \u03b2\u2011lactam\/\u03b2\u2011lactamase inhibitor combination (carbapenem meropenem + cyclic boronic acid vaborbactam)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Blocks <strong>Class A and Class C serine carbapenemases<\/strong>, restoring meropenem activity against resistant strains<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Intravenous injection<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Addresses <strong>unmet need<\/strong> in China\u2019s growing CRE infection burden<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China CRE Infection Incidence<\/strong><\/td><td>~80,000\u2011100,000 cases annually<\/td><\/tr><tr><td><strong>Current Treatment Gap<\/strong><\/td><td>Limited options; polymyxins and tigecycline have toxicity concerns<\/td><\/tr><tr><td><strong>Market Size (CRE Antibiotics)<\/strong><\/td><td>\u00a51.2\u202fbillion (US$165\u202fmillion) in 2024<\/td><\/tr><tr><td><strong>Growth CAGR<\/strong><\/td><td>18% (2024\u20112030)<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Expected \u00a53,000\u20114,000 per treatment course<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>\u00a5400\u2011600\u202fmillion<\/strong> (US$55\u201182\u202fmillion) by 2028<\/td><\/tr><tr><td><strong>Competitive Edge:<\/strong> <strong>First novel CRE therapy<\/strong> accessible in mainland China via GBA pathway; potential for <strong>national approval<\/strong> within 24 months<\/td><td><\/td><\/tr><tr><td><strong>Partnership:<\/strong> Exclusive mainland China rights from <strong>Menarini Asia-Pacific<\/strong> (licensed Aug\u202f2022)<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Meropenem\/Vaborbactam\u2019s GBA market penetration, national approval timeline, and sales potential. Actual results may differ materially due to risks including regulatory pathway changes, competitive entry, and hospital adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SciClone Pharmaceuticals Inc. announced that Meropenem\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49112,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[26,152],"class_list":["post-49094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-greater-bay-area","tag-sciclone-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SciClone&#039;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SciClone Pharmaceuticals Inc. announced that Meropenem\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau Drug and Device Access\u201d policy for use in designated medical institutions across the Greater Bay Area (GBA) mainland cities, marking the first antibiotic introduced through the GBA Medical Connect scheme and offering a breakthrough treatment for Carbapenem-resistant Enterobacterales (CRE) infections.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49094\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SciClone&#039;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect\" \/>\n<meta property=\"og:description\" content=\"SciClone Pharmaceuticals Inc. announced that Meropenem\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau Drug and Device Access\u201d policy for use in designated medical institutions across the Greater Bay Area (GBA) mainland cities, marking the first antibiotic introduced through the GBA Medical Connect scheme and offering a breakthrough treatment for Carbapenem-resistant Enterobacterales (CRE) infections.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49094\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T07:41:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-27T07:41:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SciClone&#8217;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect\",\"datePublished\":\"2025-11-27T07:41:18+00:00\",\"dateModified\":\"2025-11-27T07:41:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701.webp\",\"keywords\":[\"Greater Bay Area\",\"SciClone Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49094#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49094\",\"name\":\"SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701.webp\",\"datePublished\":\"2025-11-27T07:41:18+00:00\",\"dateModified\":\"2025-11-27T07:41:19+00:00\",\"description\":\"SciClone Pharmaceuticals Inc. announced that Meropenem\\\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau Drug and Device Access\u201d policy for use in designated medical institutions across the Greater Bay Area (GBA) mainland cities, marking the first antibiotic introduced through the GBA Medical Connect scheme and offering a breakthrough treatment for Carbapenem-resistant Enterobacterales (CRE) infections.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49094\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2701.webp\",\"width\":1080,\"height\":608,\"caption\":\"SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49094#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SciClone&#8217;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect - Insight, China&#039;s Pharmaceutical Industry","description":"SciClone Pharmaceuticals Inc. announced that Meropenem\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau Drug and Device Access\u201d policy for use in designated medical institutions across the Greater Bay Area (GBA) mainland cities, marking the first antibiotic introduced through the GBA Medical Connect scheme and offering a breakthrough treatment for Carbapenem-resistant Enterobacterales (CRE) infections.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49094","og_locale":"en_US","og_type":"article","og_title":"SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect","og_description":"SciClone Pharmaceuticals Inc. announced that Meropenem\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau Drug and Device Access\u201d policy for use in designated medical institutions across the Greater Bay Area (GBA) mainland cities, marking the first antibiotic introduced through the GBA Medical Connect scheme and offering a breakthrough treatment for Carbapenem-resistant Enterobacterales (CRE) infections.","og_url":"https:\/\/flcube.com\/?p=49094","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T07:41:18+00:00","article_modified_time":"2025-11-27T07:41:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49094#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49094"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SciClone&#8217;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect","datePublished":"2025-11-27T07:41:18+00:00","dateModified":"2025-11-27T07:41:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49094"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49094#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp","keywords":["Greater Bay Area","SciClone Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49094#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49094","url":"https:\/\/flcube.com\/?p=49094","name":"SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49094#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49094#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp","datePublished":"2025-11-27T07:41:18+00:00","dateModified":"2025-11-27T07:41:19+00:00","description":"SciClone Pharmaceuticals Inc. announced that Meropenem\/Vaborbactam for Injection has been approved under the \u201cHong Kong-Macau Drug and Device Access\u201d policy for use in designated medical institutions across the Greater Bay Area (GBA) mainland cities, marking the first antibiotic introduced through the GBA Medical Connect scheme and offering a breakthrough treatment for Carbapenem-resistant Enterobacterales (CRE) infections.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49094#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49094"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49094#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp","width":1080,"height":608,"caption":"SciClone's Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49094#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SciClone&#8217;s Meropenem-Vaborbactam Wins GBA Approval as First Antibiotic Under Medical Connect"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2701.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49094"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49094\/revisions"}],"predecessor-version":[{"id":49113,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49094\/revisions\/49113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49112"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}